MX381224B - Potentes moduladores de gamma-secretasa. - Google Patents
Potentes moduladores de gamma-secretasa.Info
- Publication number
- MX381224B MX381224B MX2017005715A MX2017005715A MX381224B MX 381224 B MX381224 B MX 381224B MX 2017005715 A MX2017005715 A MX 2017005715A MX 2017005715 A MX2017005715 A MX 2017005715A MX 381224 B MX381224 B MX 381224B
- Authority
- MX
- Mexico
- Prior art keywords
- secretase modulators
- powerful
- gamma
- powerful gamma
- aberrant
- Prior art date
Links
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 title 1
- 229940124648 γ-Secretase Modulator Drugs 0.000 title 1
- 230000001594 aberrant effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- FBKFDSUZBVDZIX-FFGDOFBPSA-N (4s)-4-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-acetamido-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-2-methylpropanoyl]amino]-3-[4-(phosphonomethyl)phenyl]propanoyl]amino]-3-(6-chloro-1h-indol-3-yl)propanoyl]amino]-5-[[1-[[(2s)-1-amino-4-meth Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NC(C)(C)C(=O)N[C@@H](CC=1C=CC(CP(O)(O)=O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=C(Cl)C=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)NC1(CC1)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(C)=O)C1=CC=CC=C1 FBKFDSUZBVDZIX-FFGDOFBPSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073553P | 2014-10-31 | 2014-10-31 | |
| PCT/US2015/058429 WO2016070107A1 (en) | 2014-10-31 | 2015-10-30 | Potent gamma-secretase modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017005715A MX2017005715A (es) | 2018-02-23 |
| MX381224B true MX381224B (es) | 2025-03-12 |
Family
ID=55858421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005715A MX381224B (es) | 2014-10-31 | 2015-10-30 | Potentes moduladores de gamma-secretasa. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10472346B2 (enExample) |
| EP (1) | EP3212633B1 (enExample) |
| JP (1) | JP6672296B2 (enExample) |
| CN (1) | CN107406423B (enExample) |
| AU (1) | AU2015338946B2 (enExample) |
| CA (1) | CA2966423C (enExample) |
| MX (1) | MX381224B (enExample) |
| WO (1) | WO2016070107A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3212633B1 (en) | 2014-10-31 | 2019-12-04 | The General Hospital Corporation | Potent gamma-secretase modulators |
| US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| JP7569688B2 (ja) | 2017-12-22 | 2024-10-18 | ハイバーセル，インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体 |
| KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| WO2020231977A1 (en) * | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| WO2021174176A1 (en) * | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Pyridazine dervatives for modulating nucleic acid splicing |
| EP4396177A1 (en) * | 2021-08-30 | 2024-07-10 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| EP0968711B9 (en) | 1997-10-28 | 2008-05-28 | Bando Chemical Industries, Ltd. | Dermatological patch sheet and process for producing base sheet therefor |
| WO2004018997A2 (en) | 2002-08-20 | 2004-03-04 | Neurogenetics, Inc. | Methods and compositions for modulating amyloid beta |
| US7244739B2 (en) | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
| JP4762250B2 (ja) | 2004-12-09 | 2011-08-31 | エフ．ホフマン−ラ ロシュ アーゲー | フェニル−ピペラジンメタノン誘導体 |
| TW201018678A (en) | 2006-01-27 | 2010-05-16 | Astrazeneca Ab | Novel heteroaryl substituted benzothiazoles |
| EP2004625B1 (en) | 2006-03-22 | 2009-12-30 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
| WO2008088881A1 (en) | 2007-01-19 | 2008-07-24 | Xcovery, Inc. | Kinase inhibitor compounds |
| US8410142B2 (en) | 2007-03-02 | 2013-04-02 | Merck Sharp & Dohme Corp. | Bipyridine carboxamide orexin receptor antagonists |
| GB0720444D0 (en) * | 2007-10-18 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
| EP2269990A4 (en) | 2008-03-25 | 2012-04-18 | Takeda Pharmaceutical | Heterocyclic compound |
| EP2401276B1 (en) | 2009-02-26 | 2013-06-05 | Eisai R&D Management Co., Ltd. | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
| JP2012051807A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | アリールイミダゾール化合物 |
| JP2012180281A (ja) | 2009-06-29 | 2012-09-20 | Dainippon Sumitomo Pharma Co Ltd | 新規オキサジアゾール誘導体 |
| NZ597505A (en) | 2009-07-15 | 2013-05-31 | Janssen Pharmaceuticals Inc | Substituted triazole and imidazole derivatives as gamma secretase modulators |
| JP2013028538A (ja) | 2009-11-13 | 2013-02-07 | Dainippon Sumitomo Pharma Co Ltd | 新規アミド誘導体 |
| WO2011120026A1 (en) | 2010-03-26 | 2011-09-29 | Glaxo Group Limited | Pyrazolyl-pyrimidines as kinase inhibitors |
| AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| JP6069661B2 (ja) | 2010-06-24 | 2017-02-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用 |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| EP2968296B1 (en) | 2013-03-12 | 2020-09-02 | The Regents of the University of California | Gamma-secretase modulators |
| EP3212633B1 (en) | 2014-10-31 | 2019-12-04 | The General Hospital Corporation | Potent gamma-secretase modulators |
-
2015
- 2015-10-30 EP EP15853792.8A patent/EP3212633B1/en active Active
- 2015-10-30 JP JP2017523912A patent/JP6672296B2/ja active Active
- 2015-10-30 AU AU2015338946A patent/AU2015338946B2/en active Active
- 2015-10-30 CA CA2966423A patent/CA2966423C/en active Active
- 2015-10-30 MX MX2017005715A patent/MX381224B/es unknown
- 2015-10-30 CN CN201580071837.8A patent/CN107406423B/zh active Active
- 2015-10-30 US US15/522,969 patent/US10472346B2/en active Active
- 2015-10-30 WO PCT/US2015/058429 patent/WO2016070107A1/en not_active Ceased
-
2019
- 2019-10-25 US US16/664,621 patent/US11117884B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3212633A1 (en) | 2017-09-06 |
| EP3212633A4 (en) | 2018-07-25 |
| WO2016070107A1 (en) | 2016-05-06 |
| CA2966423C (en) | 2023-10-24 |
| MX2017005715A (es) | 2018-02-23 |
| CA2966423A1 (en) | 2016-05-06 |
| BR112017009010A2 (pt) | 2017-12-26 |
| AU2015338946A1 (en) | 2017-06-15 |
| US10472346B2 (en) | 2019-11-12 |
| CN107406423A (zh) | 2017-11-28 |
| US11117884B2 (en) | 2021-09-14 |
| JP6672296B2 (ja) | 2020-03-25 |
| JP2017533237A (ja) | 2017-11-09 |
| US20200055840A1 (en) | 2020-02-20 |
| US20180093967A1 (en) | 2018-04-05 |
| AU2015338946B2 (en) | 2020-06-11 |
| CN107406423B (zh) | 2020-06-16 |
| EP3212633B1 (en) | 2019-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX381224B (es) | Potentes moduladores de gamma-secretasa. | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| NZ768368A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| WO2016011390A8 (en) | Irak4 inhibiting agents | |
| CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MA39956A (fr) | Analogues du benzomorphane et leur utilisation | |
| EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| EA201791096A1 (ru) | 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139 | |
| EA201891377A1 (ru) | ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ | |
| MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
| EA201990915A1 (ru) | Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения | |
| PH12017500029A1 (en) | 4,5-dihydroisoxazole derivatives as nampt inhibitors | |
| EA201890412A1 (ru) | АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы | |
| MX2016008968A (es) | Compuestos organicos. | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| EA201891688A1 (ru) | Адамантановое производное и его применение |